The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies.

Spheroids of a small-cell lung cancer (SCLC) cell line POC were used to evaluate the uptake and penetration of two antibodies recognising different SCLC antigens. Spheroids approximately 300-400 microns in diameter were incubated with 1 microgram ml-1 125I-labelled NY.3D11, an antibody which reacts with the cluster 1 group antigen (neural cell adhesion molecule; NCAM) and [125I]SWA11, which binds to the cluster w4 antigen. The rate of uptake of both antibodies was similar; an initially rapid phase was seen during the first 8 h and maximum uptake occurred by 24 h. The mean uptake per spheroid at 24 h was 0.97 ng for [125I]NY.3D11 and 0.45 ng for [125I]SWA11. An objective measurement of antibody penetration into spheroids was developed using a computerised image analysis of immunostained sections of spheroids. The concentration of antibody and incubation times were varied. Both antibodies penetrated the spheroids to a depth of 50 microns after 30 min. This increased to about 100 microns after 4 h incubation with 1 or 100 micrograms ml-1 SWA11. The results with 1 microgram ml-1 NY.3D11 were similar, but in the presence of 100 micrograms ml-1 NY.3D11 penetration into the spheroid was deep and diffuse. These results demonstrate a major concentration-dependent difference in the uptake and penetration of cluster 1 and cluster w4 antibodies in this spheroid model and they have implications for the selection of antibodies for targeted therapy of SCLC.

• Publication year

  1994

• Venue

  British Journal of Cancer

• Publication date

  1994-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/bjc.1994.47PMID 8297722PMCID 1968697
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relationship between tumour size and uptake of radiolabelled anti-CEA in a colon tumour xenograft

  2004cited by this paper
• Effect of dose escalation of a monoclonal anti-CEA IgG on tumour localisation and tissue distribution in nude mice xenografted with human colon carcinoma

  2004cited by this paper
• Biodistribution and tumour localisation of 131I SWA11 recognising the cluster w4 antigen in patients with small cell lung cancer.

  1993influential reference
• Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates.

  1992cited by this paper
• Use of multi‐cell spheroids of ovarian carcinoma as an intraperitoneal radio‐immunotherapy model: Uptake, retention kinetics and dosimetric evaluation

  1992cited by this paper
• Potent cytotoxic action of the immunotoxin SWA11-ricin A chain against human small cell lung cancer cell lines.

  1992cited by this paper
• 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.

  1992cited by this paper
• CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas.

  1992cited by this paper
• Antigens of lung cancer: results of the second international workshop on lung cancer antigens.

  1991cited by this paper
• Biodistribution of a monoclonal antibody (RNL‐1) against the neural cell adhesion molecule (NCAM) in athymic mice bearing human small‐cell lung‐cancer xenografts

  1991cited by this paper
• A monoclonal antibody (ERIC-1), raised against retinoblastoma, that recognizes the neural cell adhesion molecule (NCAM) expressed on brain and tumours arising from the neuroectoderm

  1991cited by this paper
• Diffusion and binding of monoclonal antibody TNT-1 in multicellular tumor spheroids.

  1991cited by this paper
• Selective immunotherapy of small cell cancer xenografts using 131I-labelled SWA11 antibody.

  1991cited by this paper
• Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research.

  1990cited by this paper
• Iodine-125-NRLU-10 kinetic studies and bismuth-212-NRLU-10 toxicity in LS174T multicell spheroids.

  1990cited by this paper
• Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues.

  1990cited by this paper
• Radiolocalization of human small cell lung cancer and antigen-positive normal tissues using monoclonal antibody LS2D617.

  1990cited by this paper
• Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.

  1989cited by this paper
• Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors.

  1989cited by this paper
• Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11.

  1989cited by this paper
• Effect of polarity and differentiation on antibody localization in multicellular tumour spheroid and xenograft models and its potential importance for in vivo IMMUNOTARGETING

  1989cited by this paper
• Neural cell adhesion molecule (NCAM) is the antigen recognized by monoclonal antibodies of similar specificity in small‐cell lung carcinoma and neuroblastoma

  1989cited by this paper
• Chapter 29 Antibody cross-blocking studies using a panel of monoclonal antibodies

  1988cited by this paper
• Uptake kinetics of monoclonal antibodies by human malignant melanoma multicell spheroids.

  1988cited by this paper
• Radioimmunotherapy of transplanted small cell lung cancer with 131I-labelled monoclonal antibody.

  1988cited by this paper
• Determinants of tumor blood flow: a review.

  1988cited by this paper
• Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids.

  1987cited by this paper
• The Pharmacology of Monoclonal Antibodies a

  1987cited by this paper
• Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice.

  1986cited by this paper
• Growth and cellular characteristics of multicell spheroids.

  1984cited by this paper

• Unlocking the Potential of Spheroids in Personalized Medicine: A Systematic Review of Seeding Methodologies

  2025cites this paper
• Pre-clinical models of small cell lung cancer and the validation of therapeutic targets

  2020cites this paper
• Avaliação da proliferação e migração celular mediadas pela ativação do EGFR em linhagens celulares de câncer de pulmão cultivadas como monocamadas e esferoides.

  2015cites this paper
• Potential of a Cetuximab‐based radioimmunotherapy combined with external irradiation manifests in a 3‐D cell assay

  2014cites this paper
• Antibody constructs in cancer therapy

  2007cites this paper
• Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention.

  2003influential citation
• A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells

  2003cites this paper
• Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.

  2001cites this paper
• Effect of therapeutic macromolecules in spheroids.

  2000cites this paper
• Multicellular tumour spheroids in radiation biology.

  1999cites this paper
• Biodistribution of a radiolabelled monoclonal antibody NY3D11 recognizing the neural cell adhesion molecule in tumour xenografts and patients with small-cell lung cancer.

  1998cites this paper
• Penetration and binding of monoclonal antibody in human osteosarcoma multicell spheroids. Comparison of confocal laser scanning microscopy and autoradiography.

  1996cites this paper